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Abstract
Background: Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis
(AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We
examined the association between ANCA status and relapse in two randomised controlled trials.
Methods: ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to
maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or
ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive
and ANCA-negative patients.
Results: Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the
time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed,
compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event
analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to
maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42–0.95; p = 0.026). In addition, initial proteinase 3
(PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and
mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse.
Conclusions: Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse.
Trial registration: CYCLOPS: ClinicalTrials.gov, NCT00430105. Registered retrospectively on 31 January 2007. IMPROVE:
ClinicalTrials.gov, NCT00307645. Registered retrospectively on 27 March 2006.
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Background
Granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA) are potentially life-threatening
inflammatory diseases. Whereas historically they were
almost uniformly fatal, 5-year survival is now 78% but is
often characterised by frequent relapses which are asso-
ciated with significant morbidity and mortality [1–5].
Previous studies have identified several factors associated
with an increased risk of relapse including the presence of
circulating proteinase 3 (PR3)-specific, as opposed to mye-
loperoxidase (MPO)-specific, anti-neutrophil cytoplasm
antibodies (ANCA) at the time of disease diagnosis [6, 7].
The role of ANCA testing after diagnosis in predicting
relapse has been the subject of many previous studies,
although a recent meta-analysis concluded that persistence
or a rise in ANCA titre (irrespective of specificity) during
remission was only modestly predictive of relapse [8].
Previous studies suggested that the persistence of PR3-
ANCA, but not MPO-ANCA, at the time of discontinu-
ing cyclophosphamide and switching to maintenance
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therapy is associated with an increased risk of relapse [7, 9].
We used long-term follow-up data from two of the previ-
ous European Vasculitis Study Group (EUVAS) clinical
trials, CYCLOPS and IMPROVE, to identify whether per-
sistent ANCA positivity at the time of discontinuing cyclo-
phosphamide and switching to maintenance therapy is
associated with an increased risk of relapse in patients with
moderate-to-severe ANCA-associated vasculitis (AAV)
treated with cyclophosphamide as initial remission induc-
tion therapy [10, 11].
Methods
Patient population and trial protocols
The trial databases of two EUVAS trials (CYCLOPS [10]
and IMPROVE [11]) and long-term follow-up data from
the CYCLOPS trial cohort were examined [12].
Briefly, CYCLOPS compared pulse cyclophosphamide
versus daily oral cyclophosphamide for inducing remis-
sion in 149 patients with newly diagnosed generalised
AAV from 42 centres in 13 European countries and
Mexico between 1998 and 2002. Patients received cyclo-
phosphamide until 3 months after achieving remission
(maximum 12 months) and then converted to azathio-
prine for maintenance therapy. All patients received
prednisolone, initially at 1 mg/kg body weight per day
tapered to 12.5 mg per day at the end of month 3 and to
5 mg per day by 18 months.
IMPROVE compared mycophenolate mofetil (MMF)
to azathioprine for maintenance of remission in AAV
following remission induction in 156 patients with newly
diagnosed AAV from 42 centres in 11 European coun-
tries between 2002 and 2004. Patients received either
daily oral or pulsed cyclophosphamide according to in-
vestigator preference until remission or a maximum of 6
months following which they were randomised to azathi-
oprine or MMF maintenance therapy. Both azathioprine
and MMF were withdrawn at 42 months. Prednisolone
was initially given at 1 mg/kg/day tapering to 5 mg/day
after 12 months and discontinued at 24 months [11].
For this post-hoc study, patients who were ANCA-
positive at trial entry and achieved remission following
induction therapy with cyclophosphamide were in-
cluded. Cases for which the duration of cyclophospha-
mide therapy and the time of switching to maintenance
therapy could not be determined were excluded.
Data collection
Patients in the CYCLOPS trial were initially followed-up
for 18 months. Subsequently, long-term follow-up data
were collected using physician-completed standardised
data abstraction forms [12]. The following data were col-
lected and used in this study: age and sex at diagnosis,
ANCA specificity by enzyme linked immunosorbent
assay (ELISA) at diagnosis and whether positive or
negative by ELISA at the switch to maintenance therapy,
time to clinical remission (as defined in the original trial
protocols: the complete absence of clinical disease activ-
ity using the Birmingham Vasculitis Activity Score
(BVAS) item list and supported by a normal serum C-re-
active protein (CRP) concentration [13, 14]) and conver-
sion to maintenance therapy, serum creatinine
concentration at diagnosis, clinical diagnosis (GPA vs
MPA/renal limited vasculitis), induction cyclophospha-
mide regime (pulse or daily oral cyclophosphamide), and
initial maintenance therapy received. All ANCA assays
were performed in local centres according to local pro-
tocols and reported as present or absent according to
local upper limits of normal. Patients who were positive
for both PR3- and MPO-ANCA on ELISA were classi-
fied as PR3-ANCA as previous studies have suggested
that the presence or absence of PR3-ANCA is a signifi-
cant predictor of relapse [15, 16].
Renal limited vasculitis was included with MPA based
on findings of previous studies [8, 17].
The primary outcome for this study was first relapse.
Relapses were defined in the trial protocols as a new oc-
currence or re-occurrence of major or minor organ in-
volvement attributable to active vasculitis supported by
exacerbation of at least two constitutional symptoms
and a rise in CRP [13, 14].
Statistical analyses
Categorical data are summarised as frequencies (%) and
compared using Fisher’s exact test. Continuous measure-
ments are expressed as medians (25th to 75th percentile)
and compared using Mann-Whitey U tests. Multivariate
binary logistic regression analysis was used to assess the in-
dependence of factors associated with remaining ANCA-
positive or becoming ANCA-negative and is reported as
the hazard ratio (HR) with 95% confidence interval (CI).
Relapse-free survival time was calculated from the
point of remission to first relapse and censored for death
or end of follow-up. Univariate Cox regression survival
analysis was performed and reported as HR with 95%
CI. Multivariable survival analysis was performed using
Cox regression models containing all exposures listed
above except clinical diagnosis. Clinical diagnosis was
excluded from the multivariable models since PR3-
ANCA specificity has previously been shown to be a
better predictor of relapse than disease phenotype [18].
Confirmation that all covariates included in the Cox re-
gression survival analyses met the proportional hazards
assumption was assessed graphically using log (–log)
survival curves and plotting partial residuals against
time. To determine whether the risk of effect of ANCA
status at time to switching to maintenance therapy on
risk of relapse was similar for both MPO-ANCA and
PR3-ANCA, a Cox regression model was constructed
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including both initial specificity, ANCA status at switch,
and an interaction term between the two. The Nagelkerke
pseudo R2 value for the goodness-of-fit was calculated for
two multivariable models, one including all covariates and
a second with ANCA status at switch to maintenance
therapy removed [19]. Statistical significance was defined
as a p value less than 0.05. All analyses were carried out
using IBM SPSS for Windows version 20.
Results
Patients
Two hundred and fifty-two patients met the entry cri-
teria for this study. The median length of follow-up was
4 (3.5–4.4) years with a total of 956 patient-years of
follow-up. One hundred and two patients experienced at
least one relapse during follow-up and 11 died without
experiencing a relapse. Other demographic and clinical
data, including ANCA status, is shown in Table 1.
The associations between patient characteristics and
ANCA status at the switch to maintenance therapy are
shown in Table 1. In a multivariate binary logistic re-
gression analysis patients who remained ANCA-positive
were younger (HR 0.79 (0.65–0.97) per decade; p = 0.02),
had lower serum creatinine at entry (HR 0.89 (0.81–
0.98) per 50 μmol/L; p = 0.013), and took longer to
achieve remission than those who became ANCA-
negative (HR 1.29 (1.08–1.54) per month; p = 0.005).
There was no difference in initial induction regime or
whether patients were more likely to subsequently re-
ceive MMF or azathioprine as remission maintenance
agents.
Univariate Cox regression survival analysis confirmed
that remaining ANCA-positive at the time of switching
to maintenance therapy was associated with an increased
risk of relapse (Table 2). The sensitivity, specificity, and
positive and negative predictive values of positive ANCA
for relapse and negative ANCA for no relapse are shown
in Table 3.
The median time to relapse was 19 (8–33) months for
patients who were ANCA-positive at the switch to main-
tenance therapy and 23 (14–37; p = 0.2) months for pa-
tients who were ANCA-negative at the switch to
maintenance therapy. Factors associated with an in-
creased risk of relapse were PR3-ANCA, younger age,
lower serum creatinine, GPA as a diagnosis, pulsed
intravenous cyclophosphamide, and receiving MMF
maintenance therapy.
A graphical representation of the effect of ANCA posi-
tivity at the time of switching to maintenance therapy
for all patients, and for MPO-ANCA and PR3-ANCA
patients, is shown in Fig. 1.
Prior to constructing the full multivariable Cox regres-
sion survival model we tested whether there was an inter-
action between ANCA specificity at trial entry and ANCA
status at switching to maintenance therapy. The hazard
ratio for the interaction term was close to 1 and not statis-
tically significant (HR 0.96 (0.40–2.27; p = 0.92)) suggest-
ing that there was no difference in the risk conferred by
MPO-ANCA and PR3-ANCA status at switching to
maintenance therapy. Two multivariable Cox regression
survival models were constructed: one included all covari-
ates except ANCA status at the time of switching to main-
tenance therapy (not shown); the second additionally
included ANCA status at the time of switching to main-
tenance therapy (Table 4). In both models, PR3-ANCA,
pulsed intravenous cyclophosphamide induction therapy,
MMF maintenance therapy, and younger age were associ-
ated with an increased risk of relapse. There was no in-
creased risk of relapse associated with patient gender or
age. In the second model, remaining ANCA-positive at
Table 1 Baseline characteristics of the patients and the
associations between patient characteristics and ANCA status at
switching to maintenance therapy. p refers to the difference
between the ANCA +ve and ANCA-ve status at switch to main-
tenance therapy.
All patients ANCA –ve ANCA + ve p
n (%) 252 141 (56%) 111 (44%) 0.36
Male
Female
158
94
92
49
66
45
Age (years) 59 (47–67) 62 (50–68) 54 (42–66) 0.009
Creatinine at entry
(μmol/L)
177 (108–239) 185 (126–327) 151 (97–258) 0.007
Creatinine strata
(μmol/L)
0.077
< 100
101–200
> 200
54
90
108
24
49
68
30
41
40
ANCA specificity
at entry
0.7
MPO
PR3
107
145
58
83
49
62
Diagnosis 0.45
MPA
GPA
118
134
63
78
55
56
Time to remission
(months)
3 (2.7–4.1) 3 (2–3.7) 3.2 (3–4.5) 0.001
Cyclophosphamide 0.53
Continuous
Pulse
117
135
68
73
49
62
Maintenance
therapy
0.093
AZA
MMF
Other
175
73
4
103
34
4
72
39
0
Relapse:no-relapse 102:150 47:94 55:56 0.025
ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, GPA granulomatosis
with polyangiitis, MMF mycophenolate mofetil, MPA microscopic polyangiitis, MPO
myeloperoxidase, PR3 proteinase 3
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the time of switching to maintenance therapy was associ-
ated with an increased risk of relapse and the addition of
this variable had little effect on the hazard ratios for re-
lapse associated with the other covariates in the model.
The addition of ANCA status at switching to maintenance
therapy improved the fit of the model from a pseudo R2
value of 0.24 to 0.27.
Discussion
Previous studies have consistently demonstrated a higher
risk of relapse for patients with PR3-ANCA (or cytoplas-
mic ANCA (cANCA)) at diagnosis compared to MPO-
ANCA (or perinuclear ANCA) [17, 18, 20–22]. In this
study we addressed the issue of whether persistent
ANCA at the time of switching to maintenance therapy
was associated with an increased risk of relapse. We
demonstrated that persistent ANCA at the switch to
maintenance therapy is associated with an increased risk
of relapse. In multivariable analysis, this association
remained significant after adjusting for initial cyclophos-
phamide therapy regimen, maintenance therapy, age,
and renal function. When we compared two multivari-
able models of the risk of relapse, the model including
ANCA status at the time of switching to maintenance
therapy gave a better fit to the observed risk of relapse
than the model not including ANCA status at the time
of switching to maintenance therapy.
The few studies that have previously examined this
issue were limited by smaller sample size and analyses
that were not adjusted for other known risk factors for
relapse. These studies suggested that persistent cANCA
by indirect immunofluorescence (IIF) was associated
with an increased risk of relapse compared to patients in
whom ANCA re-occurred following the switch to main-
tenance therapy or who were persistently negative in re-
mission [7, 23]. One recent underpowered retrospective
study compared the relapse rate of patients who were
cANCA-positive or cANCA-negative at the time of re-
mission and found no significant difference in relapse
risk [24]. The significance of persistent MPO-ANCA at
the time of switch to maintenance therapy was investi-
gated in 62 Japanese patients with MPA and was not
found to be associated with an increased risk of relapse,
although several studies have reported an increased risk
of relapse associated with an increase in MPO-ANCA
titre once in remission [9, 25]. Rituximab is now increas-
ingly being used for both remission induction and main-
tenance in AAV. Although several trials have reported
on re-occurrence of ANCA after initial remission induc-
tion as a risk factor for relapse, none have reported on
the ANCA status at the time of starting maintenance
therapy as a risk factor for relapse [26–28]. We tested
the overall effect of remaining ANCA-positive at switch-
ing to maintenance therapy and also looked for evidence
of an interaction between ANCA specificity and ANCA
status at switching. There was no evidence of an inter-
action between these two variables, suggesting that the
increased risk of relapse observed in patients remaining
ANCA-positive was true for both MPO-ANCA- and
PR3-ANCA-positive patients (Fig. 1).
Several factors that are recorded during routine clin-
ical practice have now been identified that associate with
an increased risk of relapse in patients with AAV: PR3-
ANCA at diagnosis, persistent ANCA at switch to main-
tenance therapy, better renal function, younger age,
pulsed cyclophosphamide for remission induction ther-
apy, MMF for maintenance therapy, corticosteroid with-
drawal, and cardiovascular system involvement [11, 12,
17, 20, 29]. Currently there is no clear evidence base to
Table 3 The sensitivity, specificity, positive predictive value, and
negative predictive value of a positive ANCA for subsequent
relapse and a negative ANCA for relapse-free survival
Positive ANCA and
relapse
Negative ANCA and no
relapse
Sensitivity 0.55 0.64
Specificity 0.63 0.55
Positive predictive value 0.50 0.68
Negative predictive value 0.68 0.50
ANCA anti-neutrophil cytoplasm antibodies
Table 2 Univariate survival analysis of factors potentially
associated with the risk of relapse during follow-up
Variable Hazard ratio (95% CI) p
ANCA at switching to maintenance therapy
ANCA-positive 1 0.004
ANCA-negative 0.57 (0.38–0.84)
ANCA at trial entry
MPO-ANCA 1 0.002
PR3-ANCA 1.99 (1.30–3.04)
Patient age (per decade) 0.79 (0.70–0.90) <0.001
Serum creatinine at entry
(per 50 μmol/L)
0.87 (0.80–0.95) 0.002
Clinical diagnosis
GPA 1 0.002
MPA 0.72 (0.59–0.89)
Initial induction treatment
Daily oral cyclophosphamide 1 0.016
Pulsed cyclophosphamide 1.64 (1.10–2.45)
Initial maintenance therapy
AZA 1 <0.001
MMF 2.13 (1.42–3.19)
Time to remission (per month) 1.07 (0.95–1.21) 0.279
ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, CI confidence
interval, GPA granulomatosis with polyangiitis, MMF mycophenolate mofetil,
MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase 3
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support decision making when considering maintenance
or discontinuation of immunosuppression once a patient
has been in remission for a period of time, although a re-
cent meta-analysis suggested that patients should receive
at least 18 months of corticosteroids to reduce the risk of
subsequent relapse [29]. This study provides additional
clinical information that can inform the discussion with
an individual patient about the risk of relapse when plan-
ning maintenance immunosuppression therapy, although
it is not possible to conclusively identify those patients
who will or will not subsequently relapse—only those with
a greater or lesser risk of relapse.
It is interesting to note that the patients who remained
ANCA-positive at switching to maintenance therapy took
longer to achieve remission than the patients who had be-
come ANCA-negative. In the absence of hard objective
measures of disease activity for AAV it is not possible to
determine whether this is a real association or whether,
because the physicians managing patients in the original
trials were not blinded to treatment or ANCA status,
knowledge of these factors influenced a physician’s judge-
ment as to when patients entered remission and were
switched to maintenance therapy. The same factors could
also potentially influence the physician’s judgement as to
whether symptoms represented relapse.
Patients in the CYCLOPS trial received cyclophospha-
mide for a longer period than the patients in the IM-
PROVE trial, and several CYCLOPS patients who were
ANCA-positive at remission became ANCA-negative by
the time of switching to maintenance therapy. Due to
the small numbers of patients affected it is not possible
to determine whether the additional cyclophosphamide
received had a significant effect on the risk of relapse.
We are not able to determine from this study the role
that ANCA plays in the development of relapse. We do
not know how many of the patients who subsequently re-
lapsed remained persistently ANCA-positive and how
many of the patients who relapsed were ANCA-positive at
the time of relapse. It is interesting to speculate whether
ANCA positivity at the time of switching to maintenance
therapy indicates a direct pathogenic role for ANCA in
the re-occurrence of disease activity or whether it is a bio-
marker for continued lack of tolerance against the autoan-
tigens and immunological resistance to treatment.
Table 4 Multivariable Cox regression survival analysis of factors
associated with risk of relapse
Variable Hazard ratio (95% CI) p
ANCA status at switch to maintenance therapy
ANCA-positive 1 0.026
ANCA-negative 0.63 (0.42–0.95)
ANCA specificity at trial entry
MPO-ANCA 1 0.005
PR3-ANCA 1.87 (1.21–2.89)
Initial induction treatment
Daily oral cyclophosphamide 1 0.045
Pulsed cyclophosphamide 1.52 (1.01–2.29)
Creatinine at entry (per 50 μmol/L) 0.89 (0.83–0.97) 0.004
Initial maintenance therapy
AZA 1 0.002
MMF 2.08 (1.38–3.13)
Age (per decade) 0.88 (0.76–1.01) 0.065
Gender 0.98 (0.65–1.49) 0.93
Time to remission 1.0 (0.87–1.15) 0.97
ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, CI confidence
interval, MMF mycophenolate mofetil, MPO myeloperoxidase, PR3 proteinase 3
Fig. 1 Kaplan-Meier survival curves demonstrating the effect of ANCA status at the time of switching to maintenance therapy on all patients (a),
and patients who were initially either PR3-ANCA-positive (b) or MPO-ANCA-positive (c). The numbers remaining at risk in the ANCA-positive and
ANCA-negative groups at each time point are shown below the appropriate survival curve. ANCA anti-neutrophil cytoplasm antibodies, MPO,
myeloperoxidase, PR3 proteinase 3
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This study is limited in that the data are derived from
two clinical trials. These studies were not designed to in-
vestigate whether remaining ANCA-positive at time of
disease remission increases the risk of disease relapse.
We also do not have data on how long the patients in
this cohort remained on maintenance immunosuppres-
sive therapy nor can we investigate the effect of cumula-
tive immunosuppression and corticosteroids on relapse
risk. However, it provides additional evidence that allows
better relapse-risk assessment for the individual patient.
It is larger than previous studies which have also sug-
gested that ANCA positivity at the time of remission in-
creases relapse risk and has demonstrated that this is
true in multivariable analysis.
It is also important to point out that patients included in
this study all received cyclophosphamide induction therapy
and all but four received azathioprine or MMF mainten-
ance therapy; thus, these results may not be applicable to
patients who have received rituximab or additional plasma
exchange as part of their remission induction regime.
Conclusions
The findings of this study provide useful information for
the clinician to help stratify patients for their future risk of
relapse. Further work is needed in understanding why per-
sistent ANCA at the time of switching is associated with an
increased risk of relapse and whether more detailed immu-
nophenotyping of these patients may reveal new thera-
peutic targets and improved understanding of the
mechanisms of AAV disease. In future this may allow us to
develop trials specifically targeting new or additional ther-
apy at patients at high risk of relapse to improve outcomes.
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